Euro-Sante :: Euro-Health

Archives for life sciences

The relevance of value in establishing the positioning of medicines is the new normal for pharmaceutical marketing. Pharmaceutical companies have customers who are highly constrained by whether healthcare system funding is sustainable long term. Remember, payers think epidemiologically and in multiple years of costed care so industry needs to assess how that can be understood […]

Posted by Mike Tremblay

The AI agenda is for me all about augmenting human reasoning; what I call cognology (cognitive focus) to distinguish from technology (physical focus). This is the core challenge to work flow and adoption. Here are some thoughts on the application of John Boyd’s OODA decision making from military decision making to healthcare decision making. Boyd […]

Posted by Mike Tremblay

This is a summary of some emerging and salient issues related to the UK departure from the EU. Workforce It is estimated that the UK recruits 7000 nurses and 2000 doctors annually from the EU. The UK is currently unable to meet its workforce requirements for the NHS from its domestic higher education system. To… » read more

Posted by EuroSante

Just about every country has identified life sciences in some form or other as a priority for academic and commercial development. But what will characterise the countries that may in the end prevail? The research community needs a high degree of autonomy. The European University Association released an interesting study, University Autonomy in Europe II:… » read more

Posted by EuroSante

There is a clutch of small states within the European Union. There are many more small states outside the EU. Much can be learned from them, as at least within the EU, some seem more robustly managed and economic productive than their larger debt-laden counterparts. Healthcare systems are often seen as requiring some degree of… » read more

Posted by EuroSante